Recent Posts
- doceree
- CAR T-cell Therapy in CLL (chronic lymphocytic leukemia): Navigating the Landscape and Looking Ahead with Catherine Coombs, MD
- Advancing Acute Lymphoblastic Leukemia Treatment with CAR-T Cells: Insights from Dr. Anjali Advani
- Utility of ctDNA in CAR-T and bispecific therapy with Dr. Brian Sworder, MD
- Nitin Jain, MD Challenging case involving advanced B-cell lymphoblastic leukemia (BLL) from the CAR-T and Bispecifics Conference [2024]
Wishing a Happy Birthday to Jeffrey Weber MD today. So important to the field of Immunotherapy. An amazing friend, mentor, leader.
@nyulangone @sitcancer @ASCO @myESMO
VIDEO: CAR T-cell Therapy in CLL (chronic lymphocytic leukemia): Navigating the Landscape and Looking Ahead with Catherine Coombs, MD https://oncologytube.com/car-t-cell-therapy-in-cll-chronic-lymphocytic-leukemia-navigating-the-landscape-and-looking-ahead-with-catherine-coombs-md/ @UCIrvineHealth @_MDEducation @Ryan_fitzpatric
Oncology Conference Videos
Oncology News
Teclistamab FDA approval biweekly dosing in Relapsed or Refractory Multiple Myeloma (3 KOL Video Interviews…
By. Joanne Kotsopoulos, MD, Date: 12/07/2023 At the SABCS 2023 conference, Joanne Kotsopoulos, MD, a researcher…
At ASH 2023, Hamza Hashmi, MD, a medical doctor and hematologist from Charleston, South Carolina,…
By. Ash Alizadeh, MD Date: 12/13/2023 At ASH 2023, Dr. Ash Alizadeh, a distinguished medical…
By: Carol Fabian, MD Date. 12/07/2023 In an interview, Carol Fabian, MD, an expert in breast…
At ASH 2023, Ola Landgren, MD, Professor of Medicine and Chief Division of Myeloma at…
Zandra Klippel, MD, Global Product Head, Sanofi – Phase 3 IsKia trial of Sarclisa® (isatuximab)…
By. Neil Carleton, MD Date. 12/07/2023 In the interview with Neil Carleton, MD, the discussion revolved…
At ASH 2023, Katherine Broome, MD, a medical doctor and medical oncologist at the Georgetown…
Allen Wilbanks finds himself at SABCS 2023, where he engages in a discussion with Dr.…
… The Medical Oncology Association of Southern California (MOASC) 2024 Summit has once again set…